2
Clinical Trials associated with Ross River virus vaccine (National Resilience)A Phase 3 Study to Assess the Immunogenicity, Safety, and Consistency of Lot Manufacture of Ross River Virus (RRV) Vaccine in Healthy Male and Female Subjects 16 Years of Age and Older
The purpose of the study is to verify the safety and adequacy of the immune response produced by a 2.5 µg, adjuvanted (aluminium hydroxide) dose of Ross River Virus (RRV) vaccine and to demonstrate the consistency of manufacture of 3 separate lots of RRV vaccine.
/ Not yet recruitingNot Applicable A BLINDED PHASE I/II DOSE ESCALATION STUDY TO ASSESS SAFETY AND IMMUNOGENICITY AND INVESTIGATE THE OPTIMAL DOSE LEVEL OF A FORMALIN-TREATED, UV-INACTIVATED, VERO CELL-DERIVED ROSS RIVER VIRUS (RRV) VACCINE IN HEALTHY VOLUNTEERS AGED 18 TO 40 YEARS - INACTIVATED ROSS RIVER VIRUS VACCINE
100 Clinical Results associated with Ross River virus vaccine (National Resilience)
100 Translational Medicine associated with Ross River virus vaccine (National Resilience)
100 Patents (Medical) associated with Ross River virus vaccine (National Resilience)
100 Deals associated with Ross River virus vaccine (National Resilience)